Clinical Trials Logo

Melasma clinical trials

View clinical trials related to Melasma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06013540 Active, not recruiting - Melasma Clinical Trials

Comparison Of Efficacy Of Combination Of TAM Formula Vs Kligman Formula For Melasma.

Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

This study would offer the participants about the knowledge of these formula in the treatment of melasma and help the investigators in incorporating and updating the management protocols in medical practice.

NCT ID: NCT06010810 Active, not recruiting - Melasma Clinical Trials

The Effectiveness of 3% Topical Tranexamic Acid Compared to 4% Topical Hydroquinone as Therapy of Melasma

Start date: June 1, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to compare 3% Topical Tranexamic Acid with 4% Topical Hydroquinone as Therapy of Melasma in Patients with Skin Type III-V. The main question[s] it aims to answer are: 1. Is there a greater decrease in mMASI score after application of 3% topical tranexamic acid compared to 4% hydroquinone in melasma patients with skin type III - V? 2. Is there a greater decrease in mexameter score after application of 3% topical tranexamic acid compared to 4% hydroquinone in melasma patients with skin type III - V? 3. Are there any side effects of topical therapy of 3% tranexamic acid cream on melasma patients with skin types III - V? Participants with melasma diagnostic will apply the tranexamic acid cream and hydroquinone cream on both sides of the face differently. Researchers will compare by measuring the mexameter score and mMasi score to see if there any decrease in both sides of the face.

NCT ID: NCT03826277 Active, not recruiting - Melasma Clinical Trials

Efficacy of Melanostop Peeling for Improvement of Melasma

VIMEL
Start date: February 1, 2019
Phase: N/A
Study type: Interventional

Participants with face melasma will receive 4 Melanostop peel treatments containing 20% azelaic acid, 10% resorcinol and 6% phytic acid. Peels will be performed at 2-week interval. They will also receive a facial tonic and cream for at home use, containing brightening ingredients: vitamin C, niacinamide, alpha arbutin, kojic acid. They will also receive sunscreen protection cream with SPF 50, protecting against UVA, UVB, HEV and IR. Products for at home use will be used twice a day, every day. Measurements will be made at baseline, on the day of the forth peel treatment and 4 weeks after the last peel. Measured parameters will be: mMASI score, VisioFace photography analysis, melasma area measurements, and melanin index, ΔE, CIELab colour measurements with Cortex SkinLab Combo (Cortex Technology Asp, Denmark).

NCT ID: NCT03456674 Active, not recruiting - Melasma Clinical Trials

LaseMD System for the Treatment of Melasma

Start date: February 7, 2018
Phase: N/A
Study type: Interventional

This study will evaluate the clinical outcomes associated with use of the LaseMD Laser System for the treatment of melasma.